Anar al contingut
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Idioma
Tots els camps
Títol
Autor
Matèria
Signatura
ISBN/ISSN
Etiqueta
Trobar
Avançada
Future of flu vaccines. Expedi...
Citar
Enviar aquest missatge de text
Enviar per correu electrònic aquest
Imprimir
Exportar registre
Exportar a RefWorks
Exportar a EndNoteWeb
Exportar a EndNote
Enllaç permanent
Future of flu vaccines. Expediting clinical trials in a pandemic.
Veure altres versions (1)
Dades bibliogràfiques
Autors principals:
Pollard, A
,
Reiner, A
,
John, T
,
Sheasby, E
,
Snape, M
,
Faust, S
,
Collinson, A
,
Finn, A
,
Heath, P
,
Miller, E
Format:
Journal article
Idioma:
English
Publicat:
2009
Fons
Descripció
Altra versió (1)
Ítems similars
Visualització del personal
Ítems similars
Future of flu vaccines. Expediting clinical trials in a pandemic.
per: Pollard, A, et al.
Publicat: (2009)
Relationships between reactogenicity and age, dose number and immunogenicity in 937 children receiving two doses of ASO3(B)-adjuvanted split virion or whole virus H1N1 influenza A 2009 pandemic vaccines
per: Walker, W, et al.
Publicat: (2011)
Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.
per: Waddington, C, et al.
Publicat: (2010)
Safety and immunogenicity of AS03 B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: Open label, randomised, parallel group, multicentre study
per: Waddington, C, et al.
Publicat: (2010)
Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age.
per: Waddington, C, et al.
Publicat: (2010)